ReviewAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2022
Emerging Theranostic Nanomaterials in Diabetes and Its Complications.
Review in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 137 citations in OpenAlex.
- Urinary microenvironment-degradable nanocapsules for traceable therapy of diabetic nephropathy.Materials today. Bio · 2026Article
- Catechol functionalized polyguluronate enriched sodium alginate wetspun fibers with immobilized platelet lysate for diabetic wound healing.RSC advances · 2026Article
- Applications of Carbon Dots and Graphene Quantum Dots in Treatment of Diabetes.Molecules (Basel, Switzerland) · 2026Review
- Network Pharmacology and Zebrafish Model Elucidate the Hypoglycemic Mechanism of Major Compounds inFoods (Basel, Switzerland) · 2026Article
- Sustainable nanomaterials for precision dental medicine: green synthesis, therapeutic applications, and future directions.Journal of nanobiotechnology · 2026Review
- Innovative microneedle-integrated hydrogels: a promising strategy for diabetic foot ulcer management.Frontiers in bioengineering and biotechnology · 2026Review
- MXenes in diabetes: diagnostic and therapeutic applications.RSC advances · 2025Review
- Review
- Antioxidant, In Vitro Cytotoxicity, and Anti-diabetic Attributes of a Drug-Free Guar Gum Nanoformulation as a Novel Candidate for Diabetic Wound Healing.Molecular biotechnology · 2025Article
- Noninvasive On-Skin Biosensors for Monitoring Diabetes Mellitus.Nano-micro letters · 2025Review
- Liraglutide-Conjugated Poly(methyl vinyl ether-ACS applied materials & interfaces · 2025Article
- Kinsenoside-Loaded Microneedle Accelerates Diabetic Wound Healing by Reprogramming Macrophage Metabolism via Inhibiting IRE1α/XBP1 Signaling Axis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- The Transformative Role of Nanotechnology in the Management of Diabetes Mellitus: Insights from Current Research.Biomolecules · 2025Review
- NIR-triggered and glucose-powered hollow mesoporous Mo-based single-atom nanozymes for cascade chemodynamic diabetic infection therapy.Materials today. Bio · 2025Article
- An MXene nanocomposite hydrogel for enhanced diabetic infected wound healing via photothermal antibacterial properties and bioactive molecule integration.Materials today. Bio · 2025Article
- Review
- Article
- Targeting tRNA-Derived Non-Coding RNA Alleviates Diabetes-Induced Visual Impairment through Protecting Retinal Neurovascular Unit.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Diabetic cardiomyopathy and COVID-19: intersecting pathways and amplified cardiovascular risk.Frontiers in pharmacology · 2025Review
- Nanotechnology-Based Approaches for the Management of Diabetes Mellitus: An Innovative Solution to Long-Lasting Challenges in Antidiabetic Drug Delivery.Pharmaceutics · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 3 countries.
Funding
Abstract
Diabetes mellitus (DM) refers to a group of metabolic disorders that are characterized by hyperglycemia. Oral subcutaneously administered antidiabetic drugs such as insulin, glipalamide, and metformin can temporarily balance blood sugar levels, however, long-term administration of these therapies is associated with undesirable side effects on the kidney and liver. In addition, due to overproduction of reactive oxygen species and hyperglycemia-induced macrovascular system damage, diabetics have an increased risk of complications. Fortunately, recent advances in nanomaterials have provided new opportunities for diabetes therapy and diagnosis. This review provides a panoramic overview of the current nanomaterials for the detection of diabetic biomarkers and diabetes treatment. Apart from diabetic sensing mechanisms and antidiabetic activities, the applications of these bioengineered nanoparticles for preventing several diabetic complications are elucidated. This review provides an overall perspective in this field, including current challenges and future trends, which may be helpful in informing the development of novel nanomaterials with new functions and properties for diabetes diagnosis and therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.